Objective. This case-control study investigated the protective efficacy against pertussis of
three doses of a two-component acellular pertussis vaccine (manufactured by Biken in …

Because of apparent differences in the incidence and epidemiology of pertussis in the
United States and Canada, we measured the antibody response to four Bordetella pertussis …

An acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-
9K/129G), filamentous haemagglutinin (FHA) and pertactin (69 kDa protein) was evaluated …

Objective: To examine induction and persistence of cell-mediated immunity (CMI) and
antibody responses toBordetella pertussisantigens in infants receiving antipertussis …

Pertussis is a unique infectious disease in that it can be severe and fatal but occurs without
fever and other evidence of an inflammatory illness. The authors with others have studied …

In an effort to determine the optimal dose of pertussis toxoid (PT) and filamentous
haemagglutinin (FHA) for use in acellular pertussis vaccines we compared the …

Background Concern about both safety and efficacy has made the use of whole-cell
pertussis vaccines controversial. In some European countries, including Italy, the rate of …

235 healthy 10–12 years old school children were randomly immunized with either a
booster dose of diphtheria-tetanus-acellular pertussis (dTap) or diphtheria-tetanus (dT) …

During the past 3 decades, great strides have been made in relation to the molecular
microbiology of Bordetella pertussis (the cause of pertussis) and the epidemiology of …